Home Psychology Systematic assessment finds extra scientific hurt than advantages in Alzheimer’s “remedies” lecanemab, aducanumab, and donanemab

Systematic assessment finds extra scientific hurt than advantages in Alzheimer’s “remedies” lecanemab, aducanumab, and donanemab

Systematic assessment finds extra scientific hurt than advantages in Alzheimer’s “remedies” lecanemab, aducanumab, and donanemab


Research ques­tions ben­e­match of recent Alzheimer’s drug (UGA Right this moment):

Final sum­mer, the U.S. Meals and Drug Admin­is­tra­tion ful­ly accepted the primary drug proven to sluggish the progress of Alzheimer’s. However new analysis from the Uni­ver­si­ty of Geor­gia sug­gests that sufferers and care­givers might not expe­ri­ence any ben­e­match from the drug of their dai­ly lives.

The drug, Leqem­bi, turned eli­gi­ble for cov­er­age by way of Medicare, mak­ing it extra afford­in a position for the mil­lions of Amer­i­cans within the ear­ly phases of the dis­ease. However specialists remained skep­ti­cal that the drug professional­vid­ed sufficient ben­e­match to jus­ti­fy the associated fee and poten­tial harms of the drug.

A brand new examine from UGA’s Mark Ebell sys­tem­at­i­cal­ly reviewed 19 pub­li­ca­tions with over 23,000 par­tic­i­pants that eval­u­at­ed eight mon­o­clon­al anti­bod­ies, includ­ing Leqembi.

We centered very clear­ly on patient-cen­tered out­comes,” stated Ebell, who’s a physi­cian and professional­fes­sor of epi­demi­ol­o­gy and bio­sta­tis­tics in UGA’s Col­lege of Pub­lic Well being. “We discovered that even after 18 to 24 months of deal with­ment, the dif­fer­ences in func­tion and cog­ni­tion between deal with­ed and untreat­ed sufferers had been so small {that a} affected person or their care­giv­er gen­er­al­ly wouldn’t discover the dif­fer­ence,” stated Ebell. “For examination­ple, the Mini-Males­tal State check has 30 pos­si­ble factors, however the dif­fer­ence seen within the stud­ies was lower than a 3rd of some extent. To be discover­capable of a affected person or their fam­i­ly, that dif­fer­ence must be a minimum of 1 to three factors.”

The examine sug­gests the drug’s hefty price, time bur­den, and poten­tial uncomfortable side effects, which embrace mind swelling and mind bleeds, might not be well worth the min­i­mal ben­e­match for many sufferers … “The poten­tial ben­e­match at all times must be weighed towards any poten­tial harms,” stated Ebell. “And it’s not by any means a clear-cut selection.”

The Research:

Clin­i­cal­ly Impor­tant Ben­e­matches and Harms of Mon­o­clon­al Anti­bod­ies Tar­get­ing Amy­loid for the Deal with­ment of Alzheimer Dis­ease: A Sys­tem­at­ic Evaluation and Meta-Analy­sis (The Annals of Fam­i­ly Med­i­cine). From the Summary:

  • PURPOSE: We con­duct­ed a meta-analy­sis to eval­u­ate clin­i­cal­ly imply­ing­ful ben­e­matches and harms of mon­o­clon­al anti­bod­ies tar­get­ing amy­loid in sufferers with Alzheimer dementia.
  • METHODS: We searched PubMed, Cochrane CENTRAL, and 5 tri­al reg­istries, in addition to the ref­er­ence lists of iden­ti­fied stud­ies … Adjustments in cog­ni­tive and func­tion­al scales had been com­pared between teams, and every dif­fer­ence was assessed to discourage­mine if it met the min­i­mal clin­i­cal­ly impor­tant dif­fer­ence (MCID).
  • RESULTS: We iden­ti­fied 19 pub­li­ca­tions with 23,202 complete par­tic­i­pants that eval­u­at­ed 8 anti-amy­loid anti­bod­ies … Not one of the adjustments, includ­ing these for lecanemab, adu­canum­ab, and donanemab, exceed­ed the MCID. Harms includ­ed sig­nif­i­cant­ly elevated dangers of amy­loid-relat­ed imag­ing abnor­mal­i­ties (ARIA)-edema, ARIA-hem­or­rhage, and symp­to­matic ARIA-edema.
  • CONCLUSIONS: Though mon­o­clon­al anti­bod­ies tar­get­ing amy­loid professional­vide small ben­e­matches on cog­ni­tive and func­tion­al scales in sufferers with Alzheimer demen­tia, these enhance­ments are far beneath the MCID for every out­come and are accom­pa­nied by clin­i­cal­ly imply­ing­ful harms.

The Research in Context:



Please enter your comment!
Please enter your name here